Cloudbreak Pharma (2592) Stock Overview
A clinical-stage ophthalmology biotechnology company, researches and develops ophthalmic drugs for chronic eye diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
2592 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Cloudbreak Pharma Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$3.85 |
| 52 Week High | HK$9.74 |
| 52 Week Low | HK$3.60 |
| Beta | 0 |
| 1 Month Change | -51.88% |
| 3 Month Change | -13.48% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -37.90% |
Recent News & Updates
Recent updates
Shareholder Returns
| 2592 | HK Biotechs | HK Market | |
|---|---|---|---|
| 7D | -23.5% | 3.5% | 1.5% |
| 1Y | n/a | 107.7% | 31.1% |
Return vs Industry: Insufficient data to determine how 2592 performed against the Hong Kong Biotechs industry.
Return vs Market: Insufficient data to determine how 2592 performed against the Hong Kong Market.
Price Volatility
| 2592 volatility | |
|---|---|
| 2592 Average Weekly Movement | 16.9% |
| Biotechs Industry Average Movement | 7.7% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in HK Market | 13.6% |
| 10% least volatile stocks in HK Market | 3.0% |
Stable Share Price: 2592's share price has been volatile over the past 3 months compared to the Hong Kong market.
Volatility Over Time: 2592's weekly volatility (17%) has been stable over the past year, but is still higher than 75% of Hong Kong stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 60 | Jinsong Ni | cloudbreakpharma.com |
Cloudbreak Pharma Inc., a clinical-stage ophthalmology biotechnology company, researches and develops ophthalmic drugs for chronic eye diseases. The company develops CBT-001, which is in Phase 3 clinical trial for treating pterygium; CBT-009, a topical formulation of atropine that is in Phase 1/2 study indicated for the treatment of juvenile myopia; CBT-004, a VEGF receptor inhibitor, which is in Phase 2 clinical trial for treating vascularised pinguecula; and CBT-006, a cholesterol dissolving molecule containing the active pharmaceutical ingredient of hydroxypropyl beta-cyclodextrins that is in Phase 2 clinical trial for the treatment of meibomian gland dysfunction associated dry eye disease. It also develops CBT-199 and CBT-145 for the treatment of presbyopia, a condition caused by an age-related process; CBT-007, an eye drop for enhancing success rate of glaucoma filtration surgery; and CBT-011, an antibody-drug-synergism conjugate for the treatment of diabetic macular edema.
Cloudbreak Pharma Inc. Fundamentals Summary
| 2592 fundamental statistics | |
|---|---|
| Market cap | HK$3.06b |
| Earnings (TTM) | -HK$325.75m |
| Revenue (TTM) | HK$79.75m |
Is 2592 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2592 income statement (TTM) | |
|---|---|
| Revenue | US$10.24m |
| Cost of Revenue | US$0 |
| Gross Profit | US$10.24m |
| Other Expenses | US$52.08m |
| Earnings | -US$41.83m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.05 |
| Gross Margin | 100.00% |
| Net Profit Margin | -408.45% |
| Debt/Equity Ratio | -105.3% |
How did 2592 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/01/06 16:31 |
| End of Day Share Price | 2026/01/06 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Cloudbreak Pharma Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.